OLI Technologies, Inc. — SEC Form D Filing

OLI Technologies, Inc. filed an SEC Form D on September 4, 2026, reporting $3.00M raised in Other Health Care.

Form D filing details

Filing
SEC Form D
Filing date
September 4, 2026
Amount reported
$3.00M
Round stage
Seed, as a $3,000,000 equity raise is the industry standard for a life sciences startup validating its core technology and preparing for early commercialization.
Industry
Other Health Care
Website
https://www.olisystems.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Traditional oligonucleotide synthesis is slow, expensive, and struggles to reliably produce the high-purity, long-chain RNA and DNA sequences required for modern genetic therapeutics.

Solution

OLI Technologies develops an automated, high-throughput synthesis platform that accelerates the custom production of high-fidelity oligonucleotides for researchers.

Why now

The rapid clinical success of mRNA vaccines and RNA-based therapies has created unprecedented global demand for scalable, rapid, and high-purity genetic material manufacturing.

Source: SEC EDGAR Form D filing